Johnson & Johnson in discussion with FDA regarding COVID-19 vaccine side effects
Johnson & Johnson said on Monday it was in discussions with the U.S. Food and Drug Administration about rare cases of a neurological disorder, Guillain-Barré syndrome, that have been reported following vaccination with the Janssen COVID-19 vaccine.
The chance of having Guillain-Barré syndrome occur is very low and the rate of reported cases exceeds the background rate by a small degree, J&J said.
The statement follows a Washington Post report on Monday, which said the FDA was expected to announce a new warning on J&J’s coronavirus vaccine related to a rare autoimmune disorder.
Guillain-Barré syndrome is a rare neurological disorder in which the body’s immune system mistakenly attacks part of its peripheral nervous system, or the network of nerves located outside of the brain and spinal cord.
Subscribe to our daily newsletter
Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.